Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting - A disproportionality analysis.
Christopher A GravelDaniel KrewskiDonald R MattisonFranco MomoliAntonios DourosPublished in: British journal of clinical pharmacology (2023)
There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2i and statins or for specific drug pairs.